Parallel Advisors’s Edwards Lifesciences EW Stock Holding History

Parallel Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.96M	Sell	49,434 -648	-1%	-$53.4K	0.07%	187
2025 Q4	$4.28M	Sell	50,082 -828	-2%	-$68K	0.08%	172
2025 Q3	$3.96M	Sell	50,910 -5,334	-9%	-$417K	0.07%	181
2025 Q2	$4.4M	Sell	56,244 -2,325	-4%	-$173K	0.09%	166
2025 Q1	$4.24M	Sell	58,569 -7,229	-11%	-$517K	0.1%	162
2024 Q4	$4.87M	Sell	65,798 -3,476	-5%	-$243K	0.11%	147
2024 Q3	$4.57M	Buy	69,274 +3,119	+5%	+$227K	0.11%	146
2024 Q2	$6.11M	Buy	66,155 +2,756	+4%	+$244K	0.16%	114
2024 Q1	$6.06M	Buy	63,399 +6,647	+12%	+$558K	0.16%	108
2023 Q4	$4.33M	Sell	56,752 -1,442	-2%	-$100K	0.13%	123
2023 Q3	$4.03M	Sell	58,194 -301	-0.5%	-$24.2K	0.13%	130
2023 Q2	$5.52M	Buy	58,495 +892	+2%	+$77.5K	0.18%	107
2023 Q1	$4.77M	Buy	57,603 +52,443	+1,016%	+$4.12M	0.16%	117
2022 Q4	$385K	Sell	5,160 -1,312	-20%	-$101K	0.02%	484
2022 Q3	$535K	Sell	6,472 -1,324	-17%	-$127K	0.02%	373
2022 Q2	$741K	Buy	7,796 +313	+4%	+$32.4K	0.03%	293
2022 Q1	$876K	Sell	7,483 -725	-9%	-$81.3K	0.03%	297
2021 Q4	$1.06M	Buy	8,208 +541	+7%	+$63.1K	0.04%	259
2021 Q3	$868K	Buy	7,667 +3,256	+74%	+$372K	0.04%	281
2021 Q2	$457K	Buy	4,411 +874	+25%	+$82.4K	0.02%	410
2021 Q1	$296K	Buy	3,537 +274	+8%	+$23.2K	0.01%	503
2020 Q4	$298K	Sell	3,263 -633	-16%	-$52.5K	0.02%	466
2020 Q3	$311K	Buy	3,896 +178	+5%	+$13.9K	0.02%	413
2020 Q2	$256K	Buy	3,718 +70	+2%	+$4.97K	0.02%	463
2020 Q1	$229K	Buy	3,648 +612	+20%	+$44.1K	0.02%	408
2019 Q4	$236K	Buy	3,036 +51	+2%	+$3.98K	0.02%	454
2019 Q3	$219K	Buy	2,985 +1,587	+114%	+$111K	0.02%	441
2019 Q2	$86K	Sell	1,398 -21	-1%	-$1.27K	0.01%	707
2019 Q1	$90K	Sell	1,419 -633	-31%	-$36.1K	0.01%	640
2018 Q4	$101K	Buy	2,052 +207	+11%	+$10.5K	0.01%	534
2018 Q3	$99K	Buy	1,845 +600	+48%	+$29.3K	0.01%	610
2018 Q2	$60K	Buy	1,245 +288	+30%	+$13.4K	0.01%	678
2018 Q1	$45K	Buy	957 +9	+0.9%	+$391	0.01%	729
2017 Q4	$36K	Buy	948 +348	+58%	+$12.8K	0.01%	803
2017 Q3	$21K	Sell	600 -9	-1%	-$343	﹤0.01%	983
2017 Q2	$23K	Sell	609 -3	-0.5%	-$110	﹤0.01%	954
2017 Q1	$22K	Buy	612 +174	+40%	+$5.45K	﹤0.01%	925
2016 Q4	$14K	Buy	+438	New	+$14.2K	﹤0.01%	988

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Parallel Advisors's EW Position: Q1 2026 in Review

Parallel Advisors reduced its Edwards Lifesciences (EW) stake by 1.3% in Q1 2026, selling an estimated $53.4K and leaving 49,434 shares worth $3.96M. The position accounts for 0.07% of the portfolio, ranked #187.

Parallel Advisors first reported a position in EW in Q4 2016 and has held it in 38 quarters since. The position peaked at $6.11M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Parallel Advisors held 49,434 shares of Edwards Lifesciences worth $3.96M as of Q1 2026.
Parallel Advisors sold 648 Edwards Lifesciences shares in Q1 2026, an estimated $53.4K.
Edwards Lifesciences made up 0.07% of Parallel Advisors's portfolio in Q1 2026, its #187 holding.
Parallel Advisors first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 38 quarters since.
Parallel Advisors's Edwards Lifesciences position peaked at $6.11M in Q2 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.